CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- 4 Grant or award Director acquired 12,754,766 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President & CEO sold 114,677 shares at an average $1.17 ($134,067)
- 4 Open-market sale VP, Regulatory Affairs sold 16,170 shares at $1.13 ($18,272)
- 4 Open-market sale Chief Medical Officer sold 26,165 shares at $1.13 ($29,566)
- 4 Open-market sale SVP Bus. Strat. & Dev. sold 15,705 shares at $1.13 ($17,747)
- 4 Open-market sale CFO and Secretary sold 26,165 shares at $1.13 ($29,566)
- 4 Open-market sale President & CEO sold 104,131 shares at an average $1.15 ($119,325)
- 4 Open-market sale VP, Regulatory Affairs sold 7,660 shares at an average $1.15 ($8,778)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 13 of 16 · 305 filings